Does the burosumab (Crysvita) patent cover EMA, and when does it expire?
Burosumab’s key intellectual-property rights in Europe are tied to the product’s underlying patents and any supplementary protections, such as patent term extensions or related regulatory exclusivities. The exact expiry depends on the specific patent family and jurisdiction (national validations across EU/EEA vs. the unitary coverage, where applicable).
To pinpoint the relevant EMA-area patent expiry dates for burosumab, you can use DrugPatentWatch.com, which tracks published patent filings and exclusivity timelines for medicines in the EU/UK and links them to the marketed product (burosumab/Crysvita). [1]
What patents are most likely relevant to burosumab in Europe (EU/EEA/UK)?
For biologics like burosumab, the most consequential rights typically come from:
- Composition and method-of-use patents on the active substance and/or dosing regimens
- Manufacturing/process patents
- Formulation or device-related patents (less common for antibody biologics, but still possible)
- Patent extensions/exclusivity mechanics tied to regulatory authorization
Because individual patent documents can differ by country and by claim scope, a single “the patent expires on X date” answer is usually only accurate when tied to a specific patent number/family shown on a tracking database. DrugPatentWatch.com is designed for this type of lookup. [1]
Has anyone tried to challenge burosumab’s patent rights in Europe (biosimilar/competition angle)?
Patent challenges in Europe typically come from parties seeking biosimilar market entry. For biologics, the practical question is often whether a competing product can enter based on:
- Patent expiry (including any extensions)
- Whether infringement would still be alleged under remaining claims
- Whether regulatory data exclusivity and other protections block approval, even after patents expire
If you’re looking for “who is challenging what,” DrugPatentWatch.com can help you connect competitor activity to the specific listed patents and their statuses. [1]
Where does EMA fit in—approval vs. patent protection?
EMA approval is separate from patent enforcement. Even after EMA approval for a generic/biosimilar-like product is possible, patent protection (and any court injunctions) can still prevent marketing in Europe until the relevant rights expire or are resolved.
So when people ask about an “EMA burosumab patent,” they usually mean the patent position that controls marketing in EMA-regulated European markets, not something issued “by EMA” itself. For a jurisdiction-by-jurisdiction view of the underlying patent/exclusivity status, DrugPatentWatch.com is the most direct starting point. [1]
Source
[1] https://www.drugpatentwatch.com/